Artiva Biotherapeutics (ARTV) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

ARTV · Stock Price

USD 12.52+10.44 (+501.92%)

Market Cap: $286.7M

Historical price data

Overview

Artiva Biotherapeutics is advancing a scalable, allogeneic NK cell therapy platform to overcome the toxicity, cost, and manufacturing limitations of current cell therapies. Its lead program, AlloNK, is in multiple Phase 1/2 trials for autoimmune diseases and B-cell malignancies, leveraging a unique combination approach with monoclonal antibodies. The company's strategy is built on a manufacturing-first approach, enabled by a strategic partnership with GC Cell, aiming to deliver safe, effective, and accessible treatments.

Autoimmune DiseasesOncology

Technology Platform

A scalable manufacturing platform for producing allogeneic, off-the-shelf NK cells from pre-selected umbilical cord blood units with high-affinity CD16 and KIR-B haplotype, designed to enhance antibody-dependent cellular cytotoxicity (ADCC) when combined with monoclonal antibodies.

Pipeline

7

7 drugs in pipeline

Drug	Indication	Stage
Allogeneic NK Cells	Refractory Rheumatoid Arthritis (RA)	Phase 2
AFM13 + AB-101 + Cyclophosphamide + Fludarabine + Interleuki...	Relapsed or Refractory Hodgkin Lymphoma	Phase 2
AB-201 + Cyclophosphamide + Fludarabine	Breast Cancer	Phase 1/2
AB-101 + Rituximab + Interleukin-2 + Cyclophosphamide + Flud...	Non Hodgkin Lymphoma	Phase 1/2
GCC2005 + Cyclophosphamide + Fludarabine	Lymphoma, T-Cell	Phase 1

Funding History

2

Total raised:$198M

Series B$120MRA Capital ManagementMay 15, 2022

Series A$78M5AM VenturesDec 15, 2020

Opportunities

Artiva's primary opportunity lies in establishing a new, accessible treatment paradigm for autoimmune diseases by demonstrating that its off-the-shelf AlloNK therapy can induce deep, durable B-cell depletion and drug-free remission.

Success in its ongoing basket trials could unlock partnerships and validate the platform for expansion into additional antibody combinations and indications.

Risk Factors

The key risks are clinical failure of the AlloNK autoimmune programs, insufficient financial runway to reach data readouts given its low market valuation, and intense competition from both autologous CAR-T and other allogeneic cell therapy approaches that may achieve success first.

Competitive Landscape

Artiva competes in the allogeneic cell therapy space against companies like Nkarta and Fate Therapeutics (focused on oncology CAR-NKs) and against autologous CAR-T developers like Cabaletta Bio in autoimmunity. Its differentiation is its non-genetically modified, antibody-combination strategy focused on autoimmunity and its scalable manufacturing.

More companies in United States →